IOmet Pharma Ltd.
USPTO PatentsView assignee record - 10 granted patents across 5 technology areas, recorded in grant years 2018–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Iomet ranks #26,599 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 5 technology areas.
- #26,599
- of 49,997 US assignees by volume
- 13th percentile
- by Innovation Score (23.8/100)
- 12.7
- avg claims per patent
- -57%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R26599 · Foreign Corporation #26,599 · 10 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 10 grants
- MID-PACK #26,599/49,997
- PHOTO-FINISH INX International Ink
- CPC-NARROW C07D · 5 areas
- INNOV-THIN 23.8/100
- CLAIMS-RICH 12.7 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -57% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: INX International Ink Co. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Iomet’s 23.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Iomet
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- IOmet Pharma · this assignee 24
IOmet Pharma · this assignee
24 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Iomet's Innovation Score is 23.8/100 (13th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Iomet?
Each dot is one of Iomet’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Iomet’s own 12.7 claims/patent is at or below the 14.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Iomet's grants concentrate
IOmet Pharma Ltd. is a focused PatentsView assignee: 5 CPC subclasses with 90% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2020. By volume, Iomet sits between INX International Ink Co. and Irresistible Materials Ltd.
Who files at IOmet's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- INX International…
INX International Ink Co.
10 patents
- Inzer Advance Des…
Inzer Advance Designs, Inc.
10 patents
- Ioengine
Ioengine, LLC
10 patents
- ION Beam Services
ION Beam Services
10 patents
- IP Power Holdings
IP Power Holdings Limited
10 patents
- IPC Systems
IPC Systems, Inc.
10 patents
- Iqor US
Iqor US Inc.
10 patents
- Irresistible Mate…
Irresistible Materials Ltd
10 patents
- Iomet Pharma ◀
IOmet Pharma Ltd.
10 patents
What this shows IOmet holds 10 patents at rank #26,553, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near IOmet
By rank, the assignees closest to #26,553 in granted patent volume.
- INX International Ink Co. #26,549 · 10 patents
- Inzer Advance Designs, Inc. #26,550 · 10 patents
- Ioengine, LLC #26,551 · 10 patents
- ION Beam Services #26,552 · 10 patents
- IP Power Holdings Limited #26,554 · 10 patents
- IPC Systems, Inc. #26,555 · 10 patents
- Iqor US Inc. #26,556 · 10 patents
- Irresistible Materials Ltd #26,557 · 10 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in IOmet's primary technology class.
Iomet's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
24 13th percentile higher than 13% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 3 | 30.0% |
| 2019 | 4 | 40.0% |
| 2020 | 1 | 10.0% |
| 2021 | 2 | 20.0% |
Which technologies does IOmet Pharma Ltd. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
IOmet Pharma Ltd.'s patent record in context - here's where to go next.
- IOmet Pharma Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 90% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #26,599 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare IOmet Pharma Ltd. against INX International Ink Co., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 23.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.